Engineered immune cells take on stubborn anemia
NCT ID NCT07324889
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment called CD19/BCMA CAR-T cell therapy for people with a severe type of autoimmune anemia that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to attack the faulty immune cells causing the disease. The study aims to check if the treatment is safe and effective in 24 adults aged 18 to 75.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.